CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 1.5: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.38BCNY354.34M · vs all stocks (USD)
Revenue (TTM)
1.01BCNY150.77M · vs all stocks (USD)
Profit Margin
-10.92%vs Biotechnology peers
Beta
0.7960xvs all stocks
52-Week Change
-1.58%vs all stocks
Market Capitalization
2.38BCNY354.34M · vs all stocks (USD)
Enterprise Value
2.72BCNY405.20M · vs all stocks (USD)
Price to Sales (TTM)
2.34xvs Biotechnology peers
Price to Book (MRQ)
1.33xvs Biotechnology peers
Enterprise to Revenue
2.69xvs Biotechnology peers
Enterprise to EBITDA
54.74xvs Biotechnology peers
Gross Margin
21.33%vs Biotechnology peers
Profit Margin
-10.92%vs Biotechnology peers
Operating Margin
-5.68%vs Biotechnology peers
Return on Assets (TTM)
-1.98%vs Biotechnology peers
Return on Equity (TTM)
-6.07%vs Biotechnology peers
Revenue (TTM)
1.01BCNY150.77M · vs all stocks (USD)
Revenue per Share (TTM)
8.89CNYUpdated Aug 21, 2026Quarterly Revenue Growth
38.60%vs Biotechnology peers
Gross Profit (TTM)
165.27MCNY24.58M · vs all stocks (USD)
EBITDA (TTM)
128.45MCNY19.10M · vs all stocks (USD)
Net Income (TTM)
-110.67MCNY-16.46M · vs all stocks (USD)
Operating Cash Flow (TTM)
-102.19MCNY-15.20M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
940.19MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
718.12MCNYFY2025 · Dec 31, 2025Gross Profit
222.07MCNYFY2025 · Dec 31, 2025Operating Income
-30.53MCNY-4.54M · vs all stocks (USD)
Pre-tax Income
-88.57MCNYFY2025 · Dec 31, 2025Income Tax Expense
-6.14MCNYFY2025 · Dec 31, 2025Net Income
-82.43MCNYFY2025 · Dec 31, 2025EBIT
-71.23MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
128.45MCNYFY2025 · Dec 31, 2025Research & Development
86.76MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
63.44MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.64MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.67MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
17.35MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.7200CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.7200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
114.43MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
114.43MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-82.43MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
40.16KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-120.57MCNYFY2025 · Dec 31, 2025Free Cash Flow
-193.39MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
243.97MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-82.43MCNYFY2025 · Dec 31, 2025Other Non-cash Items
21.13MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-174.46MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
115.19MCNYFY2025 · Dec 31, 2025Capital Expenditures
-72.82MCNYFY2025 · Dec 31, 2025Purchase of Investments
-927.90MCNYFY2025 · Dec 31, 2025Sale of Investments
864.40MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-136.31MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
358.98MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-155.78MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-8.61MCNYFY2025 · Dec 31, 2025Other Financing Charges
-34.90MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
159.68MCNYFY2025 · Dec 31, 2025Shares Outstanding
114.72MSharesUpdated Aug 21, 2026Float Shares
54.53MSharesUpdated Aug 21, 2026% Held by Insiders
56.95%vs all stocks
% Held by Institutions
1.70%vs all stocks
Total Cash (MRQ)
454.02MCNY67.52M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.00CNYUpdated Aug 21, 2026Total Debt (MRQ)
981.49MCNY145.96M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5532xvs Biotechnology peers
Current Ratio (MRQ)
1.87xvs Biotechnology peers
Book Value per Share (MRQ)
15.62CNYUpdated Aug 21, 2026Total Assets
3.34BCNY496.38M · vs all stocks (USD)
Total Current Assets
1.19BCNYFY2025 · Dec 31, 2025Total Liabilities
1.53BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.14BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
841.11MCNYFY2025 · Dec 31, 2025Total Current Liabilities
690.89MCNYFY2025 · Dec 31, 2025Cash
243.97MCNYFY2025 · Dec 31, 2025Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
243.97MCNYFY2025 · Dec 31, 2025Other Short-term Investments
120.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
147.25MCNYFY2025 · Dec 31, 2025Inventory
537.18MCNYFY2025 · Dec 31, 2025Accounts Payable
369.77MCNYFY2025 · Dec 31, 2025Short-term Debt
235.30MCNYFY2025 · Dec 31, 2025Other Current Liabilities
551.26KCNYFY2025 · Dec 31, 2025Long-term Debt
758.91MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
326.34KCNYFY2025 · Dec 31, 2025Common Stock (Book)
114.73MCNYFY2025 · Dec 31, 2025Retained Earnings
420.47MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.81BCNY268.56M · vs all stocks (USD)
Treasury Stock
20.29MCNYFY2025 · Dec 31, 202552-Week Low
13.71CNYUpdated Aug 21, 202652-Week High
24.70CNYUpdated Aug 21, 202652-Week Change
-1.58%vs all stocks
Beta
0.7960xvs all stocks
50-Day MA
17.05CNYUpdated Aug 21, 2026200-Day MA
19.91CNYUpdated Aug 21, 2026Avg 10-Day Volume
3.65MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.80MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.9700CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 1.5: grey zoneSignificant
Altman Z-Score: 1.50
Low earnings qualitySignificant
Earnings Quality Score: -1.03
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tailin Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aprilbio Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Standard Biotools Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shengda Bio-Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Deva Holding A.S.
Tier 1ProductionApproval-Gated PipelineRuleFlow